ClinicalTrials.gg
CompletedNCT04659174Updated Oct 28, 2024Results posted

An Extension Study to Assess Long-term Safety, Tolerability, and Efficacy of KarXT in Adult Patients With Schizophrenia (EMERGENT-4)

A Phase 3 interventional study of Xanomeline and Trospium Chloride Capsules in Schizophrenia, sponsored by Karuna Therapeutics. Completed at 44 sites in 2 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-10-28.

Sponsored by Karuna Therapeutics (part of Bristol-Myers Squibb) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
152
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 20 studies testing xanomeline in Schizophrenia — 9 open to participants now, 9 under way, 4 of them phase 3. xanomeline · Schizophrenia.

Enrollment
14th of 20
152 · median 178
Started
2021
with 3 others
Phase 3
14 of 20
4 open now
Registered
2nd of 20
by date
Lead sponsor
5 of 20
Karuna Therapeutics

Among the 20 studies testing xanomeline in Schizophrenia, this one is the 14th largest by enrollment, is one of 4 that started in 2021, is one of 14 in phase 3, and was the 2nd registered.

Schizophrenia

3,571 studies on the registry are indexed under Schizophrenia; 493 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

9 of the 20 studies testing xanomeline in Schizophrenia are open now, in 12 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 9 open studies →

About xanomeline

xanomeline: first FDA approval 2024 (COBENFY). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 332 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (78%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies testing xanomeline in Schizophrenia, or all of them as a file.
02

Study summary

This is a Phase 3, multicenter, 53-week, outpatient, open-label extension (OLE) study to evaluate the long-term safety, tolerability, and efficacy of KarXT in subjects with Diagnostic and Statistical Manual-Fifth Edition (DSM-5) schizophrenia who previously completed the treatment period of one of the two Phase 3 double-blind studies, KAR-007 or KAR-009. In this OLE study, all subjects will receive KarXT (a fixed combination of xanomeline 125 mg and trospium chloride 30 mg twice daily [BID]) for up to 52 weeks regardless of treatment assignment in the preceding Phase 3 acute study. The primary objective of the study is to assess the long-term safety and tolerability of KarXT in subjects with a DSM-5 diagnosis of schizophrenia. The secondary objective of this study is to assess the long-term efficacy and monitor trough concentrations of xanomeline and trospium after administration of KarXT.

03

Conditions studied

  • Schizophrenia

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subject is aged 18 to 65 years, at time of enrollment into the preceding acute study (KAR-007/009).
  2. Subject is capable of providing .

    1. A signed informed consent form must be provided before any study assessments are performed.
    2. Subject must be fluent in (oral and written) English (United States only) or local language (Ukraine only) to consent.
  3. Subject has completed the treatment period on study drug (through Day 35 -2 days) of Studies KAR-007 or KAR-009.
  4. Subject resides in a stable living situation, in the opinion of the investigator.
  5. Subject has an identified, reliable informant/caregiver willing to be able to address some questions related to certain study visits, if needed. An informant/caregiver may not be necessary if the subject has been the patient of the investigator for ≥1 year.
  6. Women of or men with sexual partners of childbearing potential must be sexually abstinent (in line with their preferred and usual lifestyle) or willing and able to use at least 1 highly effective method of during the study and for at least 7 days after the last dose of KarXT. Sperm donation is not allowed for 7 days after the final dose of KarXT.

Exclusion criteria

Exclusion Criteria:

  1. Risk for suicidal behavior during the study as determined by the investigator's clinical assessment and Columbia-Suicide Severity Rating Scale (C-SSRS).
  2. Any abnormality, including any finding(s) from the physical examination, vital signs, , or laboratory test at the end-of-treatment visit of Studies KAR-007 or KAR-009 that the investigator, in consultation with the medical monitor, would consider to jeopardize the safety of the subject.
  3. Female subject is pregnant.
  4. If, in the opinion of the investigator (and/or Sponsor), subject is unsuitable for enrollment in the study or subject has any finding that, in the view of the investigator (and/or Sponsor), may compromise the safety of the subject or affect his/her ability to adhere to the protocol visit schedule or fulfill visit requirements.
  5. Subjects with extreme concerns relating to global pandemics such as coronavirus disease 2019 (COVID-19) that preclude study participation.
  6. Risk of violent or destructive behavior.
  7. Subjects participating in another drug or device trial or planning on participating in another clinical trial during the course of the study.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
152 participants (actual)

Study arms

  • Experimental
    KarXT

    Drug: Xanomeline and Trospium Chloride Capsules

Interventions

  • DrugXanomeline and Trospium Chloride Capsules

    Drug pages: Xanomeline · Trospium chloride

    Oral xanomeline 50 mg/trospium chloride 20 mg BID on days 1-2 followed by xanomeline 100 mg/trospium chloride 20 mg BID on days 3-7. The dosage is increased to xanomeline 125 mg/trospium chloride 30 mg BID on days 8-364 unless the subject is experiencing adverse events from the xanomeline 100 mg/ trospium chloride 20 mg dose. Subjects who were increased to xanomeline 125 mg/trospium chloride 30 mg will have the option to return to xanomeline 100 mg/ trospium chloride 20 mg depending on clinical response and tolerability. Re-escalation to 125/30 BID or re-titration in cases in which the subject has been off KarXT for a longer period of time (at least a week) is allowed and will require a discussion between the principal investigator and the medical monitor.

    Also known as: KarXT

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment-Emergent Adverse Events (TEAEs)

    TEAEs are defined as events with an onset date on or after the first dose of KarXT. An Adverse Event is any symptom, physical sign, syndrome, or disease that either emerges during the study or, if present at baseline, worsens during the study, regardless of the suspected cause of the event using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 5.0.

    Time frame: From first dose to end of study (Up to approximately 53 weeks)

Secondary outcomes

  1. Number of Participants With Serious Adverse Events (SAEs)

    An SAE is any untoward medical occurrence, in the view of either the investigator or sponsor, that results in death; is life-threatening; results in inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity, and/or; is a congenital anomaly/birth defect using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 5.0.

    Time frame: From first dose to end of study (Up to approximately 53 weeks)

  2. Number of Participants With Treatment-Emergent Adverse Events (TEAE) Leading to Study Drug Discontinuation

    TEAEs are defined as events with an onset date on or after the first dose of KarXT. An Adverse Event is any symptom, physical sign, syndrome, or disease that either emerges during the study or, if present at baseline, worsens during the study, regardless of the suspected cause of the event using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 5.0.

    Time frame: From first dose to end of study (Up to approximately 53 weeks)

  3. Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 52

    The PANSS rating form contains 7 positive symptom scales, 7 negative system scales, and 16 general psychopathology symptom scales. Participants are rated from 1 to 7 on each symptom scale. The positive symptoms in schizophrenia are the excess or distortion of normal function and the negative symptoms are the diminution or loss of normal functions. PANSS total score is the sum of all 30 items with a minimum score of 30 and a maximum score of 210. Higher scores indicate more severe symptoms. Open-label Extension Baseline (OLEB) is defined as the most recent measurement prior to the first administration of study drug in KAR-008. The assessments performed on Visit 10 (Day 35) of studies KAR-007 or KAR-009 will be considered for OLEB baseline along with any additional procedures that will be performed on Day 0 of KAR-008.

    Time frame: Open-label extension baseline, week 52

  4. Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Positive Score at Week 52

    PANSS positive score is the sum of all PANSS 7 positive symptom scales with a minimum score of 7 and a maximum score of 49. Higher scores indicate more severe symptoms. Participants are rated from 1 to 7 on each symptom scale. The positive symptoms in schizophrenia are the excess or distortion of normal function such as hallucinations, delusions, grandiosity, and hostility. Open-label Extension Baseline (OLEB) is defined as the most recent measurement prior to the first administration of study drug in KAR-008. The assessments performed on Visit 10 (Day 35) of studies KAR-007 or KAR-009 will be considered for OLEB baseline along with any additional procedures that will be performed on Day 0 of KAR-008.

    Time frame: Open-labe extension baseline, week 52

  5. Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Negative Score at Week 52

    PANSS negative score is the sum of all PANSS 7 negative symptom scales with a minimum score of 7 and a maximum score of 49. Higher scores indicate more severe symptoms. Participants are rated from 1 to 7 on each symptom scale. The negative symptoms in schizophrenia are the diminution or loss of normal functions. Open-label Extension Baseline (OLEB) is defined as the most recent measurement prior to the first administration of study drug in KAR-008. The assessments performed on Visit 10 (Day 35) of studies KAR-007 or KAR-009 will be considered for OLEB baseline along with any additional procedures that will be performed on Day 0 of KAR-008.

    Time frame: Open-label extension baseline, week 52

  6. Change From Baseline in PANSS Negative Marder Factor Score at Week 52

    PANSS Negative Marder Factor Score is the sum of 5 negative scales and 2 general scales (N1. Blunted affect; N2. Emotional withdrawal; N3. Poor rapport; N4. Passive/apathetic social withdrawal; N6. Lack of spontaneity; G7. Motor retardation; and G16. Active social avoidance). Participants are rated from 1 to 7 on each symptom scale. Higher score indicates more severe symptoms. The negative symptoms in schizophrenia are the diminution or loss of normal functions. Open-label Extension Baseline (OLEB) is defined as the most recent measurement prior to the first administration of study drug in KAR-008. The assessments performed on Visit 10 (Day 35) of studies KAR-007 or KAR-009 will be considered for OLEB baseline along with any additional procedures that will be performed on Day 0 of KAR-008.

    Time frame: Open-label extension baseline, week 52

  7. Change From Baseline in Clinical Global Impression-Severity (CGI-S) Score at Week 52

    Completed independently by a clinician, the CGI-S categorizes the severity of the illness as: 1 = Normal, not at all ill; 2 = Borderline mentally ill; 3 = Mildly ill; 4 = Moderately ill; 5 = Markedly ill; 6 = Severely ill; and 7 = Among the most extremely ill patients, by asking the clinical 1 question and providing a rating based upon observed and reported symptoms, behavior, and function in the past 7 days to reflect the average severity level across the 7 days. Higher score indicates more severe illness. Open-label Extension Baseline (OLEB) is defined as the most recent measurement prior to the first administration of study drug in KAR-008. The assessments performed on Visit 10 (Day 35) of studies KAR-007 or KAR-009 will be considered for OLEB baseline along with any additional procedures that will be performed on Day 0 of KAR-008.

    Time frame: Open-label extension baseline, week 52

  8. Percentage of PANSS Responders With >=30% Reduction in PANSS Total Score at Week 52

    A PANSS responder is defined as a participant with reduction from open-label extension baseline (OLEB) of at least a 30% improvement at Week 52 in the PANSS total score. The PANSS rating form contains 7 positive symptom scales, 7 negative system scales, and 16 general psychopathology symptom scales. Participants are rated from 1 to 7 on each symptom scale. PANSS total score is the sum of all 30 items with a minimum score of 30 and a maximum score of 210. Higher scores indicate more severe symptoms. OLEB is defined as the most recent measurement prior to the first administration of study drug in KAR-008. The assessments performed on Visit 10 (Day 35) of studies KAR-007 or KAR-009 will be considered for OLEB baseline along with any additional procedures that will be performed on Day 0 of KAR-008.

    Time frame: At week 52

07

Results

Posted Oct 28, 2024

Participant flow

Participant flow — Overall Study
MilestoneKarXT Arm AKarXT Arm B
Started6884
Completed1916
Not completed4968
Withdrew: Sponsor decision to discontinue study02
Withdrew: Lost to follow-up911
Withdrew: Adverse event85
Withdrew: Withdrawal by subject1733
Withdrew: Progressive disease02
Withdrew: Other reasons02
Withdrew: Participant fails to adhere to the protocol requirements149
Withdrew: Alcohol or illegal drug use03
Withdrew: Violation of entry criteria10
Withdrew: Death01

Outcome measures

PrimaryNumber of Participants With Treatment-Emergent Adverse Events (TEAEs)

TEAEs are defined as events with an onset date on or after the first dose of KarXT. An Adverse Event is any symptom, physical sign, syndrome, or disease that either emerges during the study or, if present at baseline, worsens during the study, regardless of the suspected cause of the event using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 5.0.

Time frame:
From first dose to end of study (Up to approximately 53 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
ParticipantsKarXT Arm AKarXT Arm B
Number of Participants With Treatment-Emergent Adverse Events (TEAEs)3645
SecondaryNumber of Participants With Serious Adverse Events (SAEs)

An SAE is any untoward medical occurrence, in the view of either the investigator or sponsor, that results in death; is life-threatening; results in inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity, and/or; is a congenital anomaly/birth defect using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 5.0.

Time frame:
From first dose to end of study (Up to approximately 53 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Serious Adverse Events (SAEs)
ParticipantsKarXT Arm AKarXT Arm B
Number of Participants With Serious Adverse Events (SAEs)53
SecondaryNumber of Participants With Treatment-Emergent Adverse Events (TEAE) Leading to Study Drug Discontinuation

TEAEs are defined as events with an onset date on or after the first dose of KarXT. An Adverse Event is any symptom, physical sign, syndrome, or disease that either emerges during the study or, if present at baseline, worsens during the study, regardless of the suspected cause of the event using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 5.0.

Time frame:
From first dose to end of study (Up to approximately 53 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Adverse Events (TEAE) Leading to Study Drug Discontinuation
ParticipantsKarXT Arm AKarXT Arm B
Number of Participants With Treatment-Emergent Adverse Events (TEAE) Leading to Study Drug Discontinuation97
SecondaryChange From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 52

The PANSS rating form contains 7 positive symptom scales, 7 negative system scales, and 16 general psychopathology symptom scales. Participants are rated from 1 to 7 on each symptom scale. The positive symptoms in schizophrenia are the excess or distortion of normal function and the negative symptoms are the diminution or loss of normal functions. PANSS total score is the sum of all 30 items with a minimum score of 30 and a maximum score of 210. Higher scores indicate more severe symptoms. Open-label Extension Baseline (OLEB) is defined as the most recent measurement prior to the first administration of study drug in KAR-008. The assessments performed on Visit 10 (Day 35) of studies KAR-007 or KAR-009 will be considered for OLEB baseline along with any additional procedures that will be performed on Day 0 of KAR-008.

Time frame:
Open-label extension baseline, week 52
Reported as:
Mean · score on a scale
Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 52
score on a scaleKarXT Arm AKarXT Arm B
Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 52-9.0 ± 17.33-23.9 ± 22.06
SecondaryChange From Baseline in Positive and Negative Syndrome Scale (PANSS) Positive Score at Week 52

PANSS positive score is the sum of all PANSS 7 positive symptom scales with a minimum score of 7 and a maximum score of 49. Higher scores indicate more severe symptoms. Participants are rated from 1 to 7 on each symptom scale. The positive symptoms in schizophrenia are the excess or distortion of normal function such as hallucinations, delusions, grandiosity, and hostility. Open-label Extension Baseline (OLEB) is defined as the most recent measurement prior to the first administration of study drug in KAR-008. The assessments performed on Visit 10 (Day 35) of studies KAR-007 or KAR-009 will be considered for OLEB baseline along with any additional procedures that will be performed on Day 0 of KAR-008.

Time frame:
Open-labe extension baseline, week 52
Reported as:
Mean · score on a scale
Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Positive Score at Week 52
score on a scaleKarXT Arm AKarXT Arm B
Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Positive Score at Week 52-3.2 ± 5.85-7.8 ± 6.38
SecondaryChange From Baseline in Positive and Negative Syndrome Scale (PANSS) Negative Score at Week 52

PANSS negative score is the sum of all PANSS 7 negative symptom scales with a minimum score of 7 and a maximum score of 49. Higher scores indicate more severe symptoms. Participants are rated from 1 to 7 on each symptom scale. The negative symptoms in schizophrenia are the diminution or loss of normal functions. Open-label Extension Baseline (OLEB) is defined as the most recent measurement prior to the first administration of study drug in KAR-008. The assessments performed on Visit 10 (Day 35) of studies KAR-007 or KAR-009 will be considered for OLEB baseline along with any additional procedures that will be performed on Day 0 of KAR-008.

Time frame:
Open-label extension baseline, week 52
Reported as:
Mean · score on a scale
Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Negative Score at Week 52
score on a scaleKarXT Arm AKarXT Arm B
Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Negative Score at Week 52-2.1 ± 4.01-4.6 ± 5.06
SecondaryChange From Baseline in PANSS Negative Marder Factor Score at Week 52

PANSS Negative Marder Factor Score is the sum of 5 negative scales and 2 general scales (N1. Blunted affect; N2. Emotional withdrawal; N3. Poor rapport; N4. Passive/apathetic social withdrawal; N6. Lack of spontaneity; G7. Motor retardation; and G16. Active social avoidance). Participants are rated from 1 to 7 on each symptom scale. Higher score indicates more severe symptoms. The negative symptoms in schizophrenia are the diminution or loss of normal functions. Open-label Extension Baseline (OLEB) is defined as the most recent measurement prior to the first administration of study drug in KAR-008. The assessments performed on Visit 10 (Day 35) of studies KAR-007 or KAR-009 will be considered for OLEB baseline along with any additional procedures that will be performed on Day 0 of KAR-008.

Time frame:
Open-label extension baseline, week 52
Reported as:
Mean · score on a scale
Change From Baseline in PANSS Negative Marder Factor Score at Week 52
score on a scaleKarXT Arm AKarXT Arm B
Change From Baseline in PANSS Negative Marder Factor Score at Week 52-2.4 ± 4.22-5.1 ± 5.67
SecondaryChange From Baseline in Clinical Global Impression-Severity (CGI-S) Score at Week 52

Completed independently by a clinician, the CGI-S categorizes the severity of the illness as: 1 = Normal, not at all ill; 2 = Borderline mentally ill; 3 = Mildly ill; 4 = Moderately ill; 5 = Markedly ill; 6 = Severely ill; and 7 = Among the most extremely ill patients, by asking the clinical 1 question and providing a rating based upon observed and reported symptoms, behavior, and function in the past 7 days to reflect the average severity level across the 7 days. Higher score indicates more severe illness. Open-label Extension Baseline (OLEB) is defined as the most recent measurement prior to the first administration of study drug in KAR-008. The assessments performed on Visit 10 (Day 35) of studies KAR-007 or KAR-009 will be considered for OLEB baseline along with any additional procedures that will be performed on Day 0 of KAR-008.

Time frame:
Open-label extension baseline, week 52
Reported as:
Mean · score on a scale
Change From Baseline in Clinical Global Impression-Severity (CGI-S) Score at Week 52
score on a scaleKarXT Arm AKarXT Arm B
Change From Baseline in Clinical Global Impression-Severity (CGI-S) Score at Week 52-0.5 ± 1.12-1.2 ± 1.60
SecondaryPercentage of PANSS Responders With >=30% Reduction in PANSS Total Score at Week 52

A PANSS responder is defined as a participant with reduction from open-label extension baseline (OLEB) of at least a 30% improvement at Week 52 in the PANSS total score. The PANSS rating form contains 7 positive symptom scales, 7 negative system scales, and 16 general psychopathology symptom scales. Participants are rated from 1 to 7 on each symptom scale. PANSS total score is the sum of all 30 items with a minimum score of 30 and a maximum score of 210. Higher scores indicate more severe symptoms. OLEB is defined as the most recent measurement prior to the first administration of study drug in KAR-008. The assessments performed on Visit 10 (Day 35) of studies KAR-007 or KAR-009 will be considered for OLEB baseline along with any additional procedures that will be performed on Day 0 of KAR-008.

Time frame:
At week 52
Reported as:
Number · Percentage of participants
Percentage of PANSS Responders With >=30% Reduction in PANSS Total Score at Week 52
Percentage of participantsKarXT Arm AKarXT Arm B
Percentage of PANSS Responders With >=30% Reduction in PANSS Total Score at Week 5242.156.3

Adverse events

Collected over Participants were assessed for All-Cause Mortality, Serious Adverse Events and Other (Not Including Serious) Adverse Events from the date of first dose until study completion (Up to approximately 53 weeks).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
KarXT Arm A0/68 (0%)5/68 (7.4%)19/68 (27.9%)
KarXT Arm B1/84 (1.2%)3/84 (3.6%)31/84 (36.9%)
Most frequent serious events
Most frequent serious events
EventKarXT Arm AKarXT Arm B
SchizophreniaPsychiatric disorders2/681/84
FallInjury, poisoning and procedural complications1/680/84
AnxietyPsychiatric disorders1/680/84
HallucinationPsychiatric disorders1/680/84
DeathGeneral disorders0/681/84
InfluenzaInfections and infestations0/681/84
Most frequent other events
Most frequent other events
EventKarXT Arm AKarXT Arm B
VomitingGastrointestinal disorders2/6811/84
DyspepsiaGastrointestinal disorders5/688/84
NauseaGastrointestinal disorders6/688/84
Weight increasedInvestigations3/686/84
Dry mouthGastrointestinal disorders3/685/84
HypertensionVascular disorders3/685/84
ConstipationGastrointestinal disorders4/683/84

Baseline characteristics

Age, Continuous
Age, Continuous(Years)KarXT Arm AKarXT Arm BTotal
Mean46.8 ± 10.9443.3 ± 12.0744.9 ± 11.67
Sex: Female, Male
Sex: Female, Male(Participants)KarXT Arm AKarXT Arm BTotal
Female201838
Male4866114
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)KarXT Arm AKarXT Arm BTotal
Hispanic or Latino4812
Not Hispanic or Latino6476140
Unknown or Not Reported000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)KarXT Arm AKarXT Arm BTotal
American Indian or Alaska Native000
Asian101
Native Hawaiian or Other Pacific Islander000
Black or African American464793
White213556
Other022
Unknown or Not Reported000
08

Study locations

44 sites
  • Pillar Clinical Research
    Bentonville, Arkansas 72712, United States
  • Woodland International Research Group
    Little Rock, Arkansas 72211, United States
  • Advanced Research Center, Inc.
    Anaheim, California 92805, United States
  • Advanced Research Center Inc
    Bellflower, California 90706, United States
  • CITrials
    Bellflower, California 90706, United States
  • Proscience Research Group
    Culver City, California 90230, United States
  • Collaborative NeuroScience Research, LLC
    Garden Grove, California 92845, United States
  • California Clinical Trial Medical Group
    Glendale, California 91206, United States
  • Synergy San Diego
    Lemon Grove, California 91945, United States
  • CNS Network
    Long Beach, California 90806, United States
  • Catalina Research Institute, LLC
    Montclair, California 91763, United States
  • NRC Research Institute
    Orange, California 92868, United States
  • California Neuropsychopharmacology Clinical Research Institute
    Pico Rivera, California 90660, United States
  • California Neuropsychopharmacology Clinical Research Institute
    San Diego, California 92102, United States
  • Artemis Institute for Clinical Research
    San Diego, California 92103, United States
  • Schuster Medical Research Institute
    Sherman Oaks, California 91403, United States
  • Collaborative Neuroscience Research, LLC.
    Torrance, California 90502, United States
  • Behavioral Clinical Research, Inc.
    Hollywood, Florida 33021, United States
  • Research Centers of America
    Hollywood, Florida 33024, United States
  • Innovative Clinical Research, Inc.
    Miami Lakes, Florida 33016, United States
  • Atlanta Center for Medical Research
    Atlanta, Georgia 30331, United States
  • iResearch Atlanta, LLC
    Decatur, Georgia 30030, United States
  • Mitchell L. Glaser
    Chicago, Illinois 60622, United States
  • Uptown Research Institute
    Chicago, Illinois 60640, United States
  • AMITA Health Center for Psychiatric Research
    Hoffman Estates, Illinois 60169, United States
  • Pillar Clinical Research
    Lincolnwood, Illinois 60712, United States
  • Arch Clinical Trials
    Saint Louis, Missouri 63125, United States
  • Altea Research Institute
    Las Vegas, Nevada 89102, United States
  • Hassman Research Institute
    Berlin, New Jersey 08009, United States
  • Hassman Research Institute
    Marlton, New Jersey 08053, United States
  • Neuro-Behavioral Clinical Research, Inc.
    North Canton, Ohio 44720, United States
  • Community Clinical Research
    Austin, Texas 78754, United States
  • InSite Clinical Research
    DeSoto, Texas 75115, United States
  • Pillar Clinical Research, LLC
    Richardson, Texas 75080, United States
  • Cherkasy Regional Psychiatric Hospital of Cherkasy Regional Council, Female Department #11, Male Department #12
    Smila, Cherkasy Region 20708, Ukraine
  • Dnipropetrovsk Regional Clinical Hospital named after I.I. Mechnikov
    Dnipro, 49005, Ukraine
  • Institute of Neurology, Psychiatry and Narcology of the National Academy of Medical Sciences of Ukraine
    Kharkiv, 61068, Ukraine
  • Regional Clinical Psychiatric Hospital No. 3, Adult Psychiatric Department No. 3
    Kharkiv, Ukraine
  • Kherson Regional Insititution of Mental Care of Kherson Regional Council Male Psychiatric Department #3, Femail Psychiatric Department #10
    Kherson, 73488, Ukraine
  • Kyiv Regional Medical Incorporation "Psychiatry", Center for Novel Treatment and Rehabilitation of Psychotic Disorders
    Kyiv, 04080, Ukraine
  • Lviv Regional Clinical Psychiatric Hospital, Department #20
    Lviv, 79021, Ukraine
  • Lviv Regional Clinical Psychiatric Hospital, Department #25
    Lviv, 79021, Ukraine
  • Regional Facility for Psychiatric Care of Poltava Regional Council, 2-A acute general psychiatric male ward, 5-B acute, quiet, general psychiatric female ward, Poltava State Medical University, Academic Department of Psychiatry, Addictology and Medical
    Poltava, 36013, Ukraine
  • M.I. Pyrogov Vinnytsya National Medical University
    Vinnytsya, 21037, Ukraine
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2021 to primary completion in Oct 2023, 32 months.

Results were first posted in Oct 2024, 1 year after primary completion.

Of 99 industry-sponsored phase 3 interventional studies under Schizophrenia, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 41. This study's 32 months is close to that.

Counting every sponsor, half of 113 studies reached it within 32 months; a quarter within 20 and three quarters within 46.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 2, 2020
First posted
Dec 9, 2020
StartActual
Feb 1, 2021
Primary completionActual
Oct 3, 2023
CompletionActual
Oct 3, 2023
Results first posted
Oct 28, 2024
Last update
Oct 28, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 28, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04659174
Responsible party
Sponsor
First posted
Dec 9, 2020
Start date
Feb 1, 2021
Primary completion
Oct 3, 2023
Completion
Oct 3, 2023
Results posted
Oct 28, 2024
Last update
Oct 28, 2024

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Xanomeline · Trospium chloride

Start the discussion